TauRx Pharmaceuticals Ltd - Company & Market Research Reports

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. The company's best known product, LMTX, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. The LMTX Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

From
From
From
From
From
From
From
Tau Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Tau Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 260 Pages
From
From
From
From
From
  • 19 Results (Page 1 of 1)
Loading Indicator
adroll